Analytical Data
-
Gene name
PDE9A
- Application
-
Alternative Names
PDE9A；High affinity cGMP-specific 3'.5'-cyclic phosphodiesterase 9A
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O76083-2
-
Expression Region
1-533aa
-
AA Sequence
MGSGSSSYRPKAIYLDIDGRIQKVIFSKYCNSSDIMDLFCIATGLPRNTT ISLLTTDDAMVSIDPTMPANSERTPYKVRPVAIKQLSEREELIQSVLAQV AEQFSRAFKINELKAEVANHLAVLEKRVELEGLKVVEIEKCKSDIKKMRE ELAARSSRTNCPCKYSFLDNHKKLTPRRDVPTYPKYLLSPETIEALRKPT FDVWLWEPNEMLSCLEHMYHDLGLVRDFSINPVTLRRWLFCVHDNYRNNP FHNFRHCFCVAQMMYSMVWLCSLQEKFSQTDILILMTAAICHDLDHPGYN NTYQINARTELAVRYNDISPLENHHCAVAFQILAEPECNIFSNIPPDGFK QIRQGMITLILATDMARHAEIMDSFKEKMENFDYSNEEHMTLLKMILIKC CDISNEVRPMEVAEPWVDCLLEEYFMQSDREKSEGLPVAPFMDRDKVTKA TAQIGFIKFVLIPMFETVTKLFPMVEEIMLQPLWESRDRYEELKRIDDAM KELQKKTDSLTSGATEKSRERSRDVKNSEGDCA
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PDE9A (phosphodiesterase 9A) is an important enzyme involved in the hydrolysis of cyclic GMP (cGMP), a critical signaling molecule in various physiological processes, including vascular smooth muscle relaxation, neuronal signaling, and cell proliferation. Dysregulation of cGMP levels has been implicated in several diseases, including cardiovascular disorders, neurodegenerative diseases, and certain types of cancer. The study of PDE9A and the development of recombinant PDE9A proteins have gained attention due to their potential applications in therapeutic interventions. Understanding the structure and function of PDE9A can facilitate the design of selective inhibitors that may serve as novel treatments for these conditions. Moreover, the ability to produce recombinant PDE9A in a laboratory setting allows researchers to investigate its biochemical properties, interaction with other cellular components, and role in signal transduction pathways. By elucidating these aspects, researchers aim to explore the therapeutic pathways that can be targeted for drug development, providing new hope for patients suffering from PDE9A-related pathologies. Hence, the study of recombinant PDE9A proteins is not only crucial for basic research but also holds promise for advancing medical therapies.
